Scholarlink

Background <p>Diabetic retinopathy (DR) is a leading cause of vision loss in diabetic patients, yet early diagnostic biomarkers and targeted therapies remain limited. While miR-106a-5p has been linked to inflammatory and metabolic regulation, its role in DR remains poorly characterized.</p> Objective <p>This study mainly explores the diagnostic value and molecular mechanism of miR-106a-5p/<i>CREB1</i> in DR.</p> Methods <p>The relative expression of miR-106a-5p in 50 patients with diabetes only (NDR) and 60 patients with DR was detected by qRT-PCR. Construct a high glucose-induced ARPE-19 cell model to evaluate changes in cell proliferation, inflammatory factors such as TNF-α, IL-6, IL-1β, and <i>CREB1</i> expression after transfection with miR-106a-5p mimetics. Dual luciferase validation of miR-106a-5p/<i>CREB1</i> target. Clinical correlations were analyzed by Pearson and logistic regression.</p> Results <p>miR-106a-5p was significantly downregulated in DR compared to NDR (<i>P</i> &lt; 0.0001), and the ROC curve indicated that miR-106a-5p had high accuracy in DR diagnosis (AUC = 0.85). It correlated inversely with FPG (<i>r</i> = − 0.77), HbA1c (<i>r</i> = − 0.68), and inflammatory markers (IL-6, TNF-α). Binary logic analysis identified miR-106a-5p as a risk factor for diabetic retinopathy (OR = 0.08, <i>P</i> &lt; 0.001). In vitro, miR-106a-5p overexpression attenuated HG-induced inflammation by targeting <i>CREB1</i> (<i>P</i> &lt; 0.0001).</p> Conclusion <p>miR-106a-5p is considered an innovative biomarker for the detection of DR, research is exploring the part of miR-106a-5p/<i>CREB1</i> in regulating inflammation as well as affecting DR occurrence, providing new ideas for DR treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

miR-106a-5p targets CREB1 to regulate the inflammatory response in diabetic retinopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Lijuan Wu,
  • Huan Li,
  • Jia Li

摘要

Background

Diabetic retinopathy (DR) is a leading cause of vision loss in diabetic patients, yet early diagnostic biomarkers and targeted therapies remain limited. While miR-106a-5p has been linked to inflammatory and metabolic regulation, its role in DR remains poorly characterized.

Objective

This study mainly explores the diagnostic value and molecular mechanism of miR-106a-5p/CREB1 in DR.

Methods

The relative expression of miR-106a-5p in 50 patients with diabetes only (NDR) and 60 patients with DR was detected by qRT-PCR. Construct a high glucose-induced ARPE-19 cell model to evaluate changes in cell proliferation, inflammatory factors such as TNF-α, IL-6, IL-1β, and CREB1 expression after transfection with miR-106a-5p mimetics. Dual luciferase validation of miR-106a-5p/CREB1 target. Clinical correlations were analyzed by Pearson and logistic regression.

Results

miR-106a-5p was significantly downregulated in DR compared to NDR (P < 0.0001), and the ROC curve indicated that miR-106a-5p had high accuracy in DR diagnosis (AUC = 0.85). It correlated inversely with FPG (r = − 0.77), HbA1c (r = − 0.68), and inflammatory markers (IL-6, TNF-α). Binary logic analysis identified miR-106a-5p as a risk factor for diabetic retinopathy (OR = 0.08, P < 0.001). In vitro, miR-106a-5p overexpression attenuated HG-induced inflammation by targeting CREB1 (P < 0.0001).

Conclusion

miR-106a-5p is considered an innovative biomarker for the detection of DR, research is exploring the part of miR-106a-5p/CREB1 in regulating inflammation as well as affecting DR occurrence, providing new ideas for DR treatment.